Neoadjuvant chemotherapy (NCT) of breast cancer enabled improved outcomes especially in patients with advanced and inflammatory diseases. Biological heterogeneity of these tumors, however, requires better molecular characterization of the malignant tissue with consequent individualization in the selection of appropriate agents. To date, numerous molecular markers have been identified, and some of them (e.g., measurement of hormonal or growth factors receptors) are already routinely used for breast cancer classification before NCT. In the present article, we summarize current knowledge about established as well as promising biomarkers which have demonstrated prognostic or predictive value in NCT of breast cancer.
- MeSH
- adjuvantní chemoterapie MeSH
- antigen Ki-67 analýza MeSH
- cyklofosfamid terapeutické užití MeSH
- doxorubicin terapeutické užití MeSH
- fluorouracil terapeutické užití MeSH
- humanizované monoklonální protilátky terapeutické užití MeSH
- lidé MeSH
- nádorové biomarkery analýza MeSH
- nádory prsu farmakoterapie imunologie metabolismus MeSH
- neoadjuvantní terapie * MeSH
- prognóza MeSH
- receptor erbB-2 analýza MeSH
- receptory pro estrogeny analýza MeSH
- receptory progesteronu analýza MeSH
- taxoidy terapeutické užití MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- MeSH
- chronická nemoc MeSH
- extrahepatální cholestáza MeSH
- financování organizované MeSH
- homeostáza účinky léků MeSH
- játra účinky léků MeSH
- modely nemocí na zvířatech MeSH
- poruchy metabolismu železa MeSH
- potkani Wistar MeSH
- pravastatin MeSH
- statistika jako téma MeSH
- železo metabolismus MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- abstrakty MeSH
ATP-binding cassette (ABC) drug efflux transporters limit intracellular concentration of their substrates by pumping them out of cell through an active, energy dependent mechanism. Several of these proteins have been originally associated with the phenomenon of multidrug resistance; however, later on, they have also been shown to control body disposition of their substrates. P-glycoprotein (Pgp) is the first detected and the best characterized of ABC drug efflux transporters. Apart from tumor cells, its constitutive expression has been reported in a variety of other tissues, such as the intestine, brain, liver, placenta, kidney, and others. Being located on the apical site of the plasma membrane, Pgp can remove a variety of structurally unrelated compounds, including clinically relevant drugs, their metabolites, and conjugates from cells. Driven by energy from ATP, it affects many pharmacokinetic events such as intestinal absorption, brain penetration, transplacental passage, and hepatobiliary excretion of drugs and their metabolites. It is widely believed that Pgp, together with other ABC drug efflux transporters, plays a crucial role in the host detoxication and protection against xenobiotic substances. On the other hand, the presence of these transporters in normal tissues may prevent pharmacotherapeutic agents from reaching their site of action, thus limiting their therapeutic potential. This chapter focuses on P-glycoprotein, its expression, localization, and function in nontumor tissues and the pharmacological consequences hereof.
- MeSH
- biologický transport fyziologie MeSH
- ledviny metabolismus MeSH
- lidé MeSH
- mozek metabolismus MeSH
- P-glykoprotein genetika metabolismus MeSH
- placenta metabolismus MeSH
- polymorfismus genetický MeSH
- těhotenství MeSH
- tenké střevo metabolismus MeSH
- testis cytologie metabolismus MeSH
- tkáňová distribuce MeSH
- xenobiotika metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- MeSH
- financování organizované MeSH
- Publikační typ
- abstrakty MeSH
- MeSH
- financování organizované MeSH
- Publikační typ
- abstrakty MeSH
